Reyedar

Overview
News
Age Tech?
Product stageSegments
Minimum Viable Product
?
Healthcare and Wellness
?

Netherlands-based Reyedar (formerly known as Reperio Medtech) is developing an eye-tracking diagnostic solution to detect the symptoms of degenerative diseases such as multiple sclerosis, Parkinson’s disease, and glaucoma. The solution uses eye-tracking sensors and deep learning AI to measure a patient’s potential to develop age-related diseases. 

The company was spun out of the ophthalmology department at the University Medical Center Groningen and plans to operate on a B2B2C basis, offering its solution to opticians, optometrists, and eye doctors for expedited diagnostic capabilities.


HQ location:
L.J. Zielstraweg 2 Groningen NLD
Founded year:
2019
Employees:
11-50
IPO status:
Private
Total funding:
USD 3.3 mn
Last Funding:
USD 3.3 mn (Seed; Jul 2023)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.